Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Lin-Wen Wu"'
Autor:
Xu Lin, Ye-han Liu, Huan-qi Zhang, Lin-wen Wu, Qi Li, Jun Deng, Qingyi Zhang, Yuhong Yang, Chong Zhang, Yang-ling Li, Jian Hu
Publikováno v:
Cancer Cell International, Vol 23, Iss 1, Pp 1-16 (2023)
Abstract Lung cancer is a leading cause of cancer-related deaths, and the most common type is lung adenocarcinoma (LUAD). LUAD is frequently diagnosed in people who never smoked, patients are always diagnosed at advanced inoperable stages, and the pr
Externí odkaz:
https://doaj.org/article/dba53029d6364141863fbe0bb3e9d577
Autor:
Yang-ling Li, Man-man Zhang, Lin-wen Wu, Ye-han Liu, Zuo-yan Zhang, Ling-hui Zeng, Neng-ming Lin, Chong Zhang
Publikováno v:
Journal of Biomedical Science, Vol 29, Iss 1, Pp 1-19 (2022)
Abstract Background Hepatocellular carcinoma (HCC) accounts for the majority of liver cancer cases, while metastasis is considered the leading cause of HCC-related death. However, the currently available treatment strategies for efficient suppression
Externí odkaz:
https://doaj.org/article/3e90ba0444124405bd834aefc6813435
Autor:
Jun Deng, Xu Lin, Qi Li, Xiao-yu Cai, Lin-wen Wu, Wei Wang, Bo Zhang, Yang-ling Li, Jian Hu, Neng-ming Lin
Publikováno v:
Cancer Cell International, Vol 22, Iss 1, Pp 1-14 (2022)
Abstract Background Inositol Polyphosphate-5-Phosphatase B (INPP5B), a inositol 5-phosphatase, plays an important role in many biological processes through phosphorylating PI(4,5)P2 and/or PI(3,4,5)P3 at the 5-position. Nevertheless, little is known
Externí odkaz:
https://doaj.org/article/739babbae8f6451eafb8f8ddf76df26a
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Oncogene. 39:6203-6217
Clear cell renal cell carcinoma (ccRCC) is the most common renal cancer and frequently diagnosed at an advanced stage. It is prone to develop unpredictable metastases even with proper treatment. Antiangiogenic therapy is the most effective medical tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f4d74126873ce059e87225b7188afe5
https://doi.org/10.1038/s41388-020-01428-3
https://doi.org/10.1038/s41388-020-01428-3
Autor:
Yang-ling Li, Shuang Xu, Dongmei Zhou, Lin-wen Wu, Chong Zhang, Ming-jun Rao, Neng-ming Lin, Zuo-yan Zhang
Publikováno v:
Cancer Biology & Medicine
Cancer Biology & Medicine, Vol 17, Iss 2, Pp 387-400 (2020)
Cancer Biology & Medicine, Vol 17, Iss 2, Pp 387-400 (2020)
Objective: Mcl-1 overexpression confers acquired resistance to Bcl-2 inhibitors in non-small cell lung cancer (NSCLC), but no direct Mcl-1 inhibitor is currently available for clinical use. Thus, novel therapeutic strategies are urgently needed to ta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f2438d347d1f0480f3aa989b9db0c50
https://doi.org/10.20892/j.issn.2095-3941.2019.0380
https://doi.org/10.20892/j.issn.2095-3941.2019.0380
Autor:
Chong Zhang, Lin-Wen Wu, Zhi-Di Li, Man-Man Zhang, Jie Wu, Fei-Hua Du, Ling-Hui Zeng, Yang-Ling Li
Publikováno v:
International journal of oncology. 60(4)
Hypoxia promotes drug resistance and induces the expression of hypoxia inducible factor (HIF)‑1α in liver cancer cells. However, to date, no selective HIF‑1α inhibitor has been clinically approved. The aim of this study is to investigate a drug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::270192f654e5ce70d69258855733dc24
https://pubmed.ncbi.nlm.nih.gov/35244188
https://pubmed.ncbi.nlm.nih.gov/35244188
Publikováno v:
OncoTargets and Therapy. 12:4585-4593
Purpose Pancreatic carcinoma is one of the most deadliest types of cancer, and relatively insensitive to the currently available chemotherapy. Thus, the discovery of novel therapeutic agents to prolong the survival times of patients with pancreatic c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::053093895b2312afaa2f7c908e671fbc
https://doi.org/10.2147/ott.s205097
https://doi.org/10.2147/ott.s205097
Autor:
Hua-jian Zhu, Dong-mei Zhou, Lin-wen Wu, Zuo-yan Zhang, Jian-kang Zhang, Neng-ming Lin, Chong Zhang
Publikováno v:
Biochemical and Biophysical Research Communications. 512:852-858
Regorafenib has been approved to treat patients who have HCC progression after sorafenib failure, however, regorafenib also faces the risk of drug resistance and subsequent progression of HCC patients. As LSD1 inhibitors can alleviate acquired resist
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::163f0b6f5410b561478cdaac348969dd
https://doi.org/10.1016/j.bbrc.2019.03.154
https://doi.org/10.1016/j.bbrc.2019.03.154
Autor:
Jiaan Shao, Huajian Zhu, Zuo-yan Zhang, Yang-ling Li, Lin-wen Wu, Neng-ming Lin, Jiankang Zhang, Linghui Zeng, Hui Chen, Chong Zhang, Xiu Hu
Publikováno v:
Phytomedicine : international journal of phytotherapy and phytopharmacology. 68
Background NSCLC is the major type of lung cancer and the survival rates of NSCLC patients remain low. AZD9291 is a third-generation EGFR-TKI and approved to treat NSCLC patients harboring EGFR T790M mutation and common targetable activating EGFR mut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9797a3646454fc8ff927bd3e557ad252
https://pubmed.ncbi.nlm.nih.gov/32070867
https://pubmed.ncbi.nlm.nih.gov/32070867